Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
CA 2476594 C · Owner: Jones, David R. · Inventors: Avor, Kwasi; Jones, David R.; Mjalli, Adnan M. M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides certain compounds of formula I wherein Al is O S or -, N(R2)-, and methods of their preparation pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are , useful as modulators of the interaction between the receptor for advanced glycated end , products (RAGE) and its ligands such as advanced glycated end products (AGEs), S 100/calgranulin/EN-RAGE, .beta..beta.-amyloid and amphoterin and for the , management, treatment, control or as an adjunct treatment for diseases in humans caused by RAGE. , Such diseases or disease states include acute and chronic inflammation the , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 5, 2003 and granted October 9, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 5, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 5, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.